KR20240110819A - Dsg2 조성물 및 방법 - Google Patents

Dsg2 조성물 및 방법 Download PDF

Info

Publication number
KR20240110819A
KR20240110819A KR1020247018502A KR20247018502A KR20240110819A KR 20240110819 A KR20240110819 A KR 20240110819A KR 1020247018502 A KR1020247018502 A KR 1020247018502A KR 20247018502 A KR20247018502 A KR 20247018502A KR 20240110819 A KR20240110819 A KR 20240110819A
Authority
KR
South Korea
Prior art keywords
dsg2
protein
seq
region
isolated polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018502A
Other languages
English (en)
Korean (ko)
Inventor
쉬 인 푸
리안 에드워드 타일러
Original Assignee
아르바다 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르바다 테라퓨틱스 인코포레이티드 filed Critical 아르바다 테라퓨틱스 인코포레이티드
Publication of KR20240110819A publication Critical patent/KR20240110819A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247018502A 2021-11-02 2022-11-02 Dsg2 조성물 및 방법 Pending KR20240110819A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274707P 2021-11-02 2021-11-02
US63/274,707 2021-11-02
PCT/US2022/079106 WO2023081674A1 (en) 2021-11-02 2022-11-02 Dsg2 compositions and methods

Publications (1)

Publication Number Publication Date
KR20240110819A true KR20240110819A (ko) 2024-07-16

Family

ID=84569745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018502A Pending KR20240110819A (ko) 2021-11-02 2022-11-02 Dsg2 조성물 및 방법

Country Status (12)

Country Link
US (1) US20240279304A1 (https=)
EP (1) EP4426430A1 (https=)
JP (1) JP2024540220A (https=)
KR (1) KR20240110819A (https=)
CN (1) CN118369351A (https=)
AR (1) AR127555A1 (https=)
AU (1) AU2022382972A1 (https=)
CA (1) CA3236070A1 (https=)
IL (1) IL312219A (https=)
MX (1) MX2024005327A (https=)
TW (1) TW202334190A (https=)
WO (1) WO2023081674A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965197A (en) 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US8093016B2 (en) 2007-05-21 2012-01-10 Danisco Us Inc. Use of an aspartic protease (NS24) signal sequence for heterologous protein expression
US8324578B2 (en) 2008-09-30 2012-12-04 Apple Inc. Hidden sensors in an electronic device
US8975041B2 (en) 2009-09-10 2015-03-10 Biocon Limited Fusion proteins and method of expression thereof
JP2012107935A (ja) * 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Ｄｅｓｍｏｇｌｅｉｎ−２蛋白質による脳梗塞の検査方法
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
US20190353652A1 (en) * 2017-01-13 2019-11-21 The Hospital For Sick Children Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy
WO2022132854A1 (en) * 2020-12-15 2022-06-23 Arvada Therapeutics, Inc. Dsg2 compositions and methods for the treatment of covid-19

Also Published As

Publication number Publication date
JP2024540220A (ja) 2024-10-31
AR127555A1 (es) 2024-02-07
IL312219A (en) 2024-06-01
CN118369351A (zh) 2024-07-19
AU2022382972A1 (en) 2024-05-09
TW202334190A (zh) 2023-09-01
CA3236070A1 (en) 2023-05-11
EP4426430A1 (en) 2024-09-11
US20240279304A1 (en) 2024-08-22
MX2024005327A (es) 2024-05-21
WO2023081674A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
KR102833432B1 (ko) 조직 석회화의 치료 방법
KR20150121715A (ko) Ｃｓｆ１ 치료제
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
CN119548617B (zh) 重组xvii型人源化胶原蛋白的新用途
JP2023126760A (ja) 抗炎症剤
CA3202364A1 (en) Dsg2 compositions and methods for the treatment of covid-19
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
Quagliata et al. Therapeutic applications of thymosin peptides: a patent landscape 2018-present
US20220315633A1 (en) Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake
US20240279304A1 (en) Dsg2 compositions and methods
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
EP1608396B1 (en) Use of soluble cd14 for treatment of diseases
EP3539561A1 (en) Therapeutic agent for cerebral infarction
KR20260040257A (ko) Hb-egf/egfr 경로 활성화와 관련된 신장 질환치료에서 사용하기 위한 hb-egf 억제제 및 코르티코스테로이드 제제의 조합
WO2022020544A1 (en) Method of treating an inflammatory condition
WO2025076208A1 (en) Compositions and methods for treating pain disorders
KR20240138585A (ko) Nampt 유래 펩타이드를 유효성분으로 포함하는 염증성 장 질환 개선, 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000